<DOC>
	<DOCNO>NCT02602275</DOCNO>
	<brief_summary>The purpose study explore effect Neurexan® brain response participant undergo emotional stressful condition verum compare placebo .</brief_summary>
	<brief_title>Neuronal Correlates Neurexan® Action Mildly Moderately Stressed Probands</brief_title>
	<detailed_description>A randomized placebo-controlled , double-blind , two-period crossover study explorative design . 40 healthy male age 31-59 year include study . Participant allocation either Neurexan® Placebo study start randomize ratio 1:1 , i.e . 20 Neurexan® first 20 Placebo first individual . Participants receive totally three tablet either Neurexan® Placebo per treatment period orally .</detailed_description>
	<mesh_term>Fractures , Stress</mesh_term>
	<mesh_term>Stress Disorders , Traumatic , Acute</mesh_term>
	<criteria>1 . Male 2 . Age ≥31 ≤59 year 3 . Fluent German language 4 . Nonsmoker 5 . Able understand explanation instruction give study physician 6 . Willing adhere prohibition restriction specify protocol 7 . Healthy basis clinical laboratory test , physical examination , medical history , vital sign perform Screening Visit 8 . Magnetic Resonance Imaging ( MRI ) compatible 9 . Participants must sign write informed consent document prior study procedure indicate understand purpose procedure require study willing participate study 10 . Trier Inventory Chronic Stress ( TICS ) Score ≥ 9 ≤ 36 11 . Perceived Stress Scale ( PSS ) &gt; 9 1 . Current past history psychotic feature diagnosis psychiatric disorder define Diagnostic Statistical Manual Mental Disorder 4th edition ( DSMIV ) Axis I ( recurrent major depression , panic disorder , social phobia , obsessivecompulsory disorder ; alcohol dependency ; schizophrenia mania ) 2 . History depressive episode last 3 month prior Screening Visit 3 . Use psychotropic medication suffer severe psychiatric illness last 3 month prior Screening Visit 4 . Intake prescription drug sleep disorder nervousness within one month prior Screening Visit 5 . Intake counter ( OTC ) medication treatment sleep disorder nervousness within last ( one ) week prior Screening Visit 6 . High chronic stress verify TICSSSCS ( &gt; 36 ) 7 . Low chronic stress verify TICSSSCS ( &lt; 9 ) PSS ≤ 9 8 . Participants Blood Pressure ( BP ) ≥ 160/100 day 0 randomization 9 . Participants treat hypertension 10 . Known allergy and/or hypersensitivity ingredient Neurexan® ( Passiflora incarnata , Avena sativa , Coffea arabica , Zincum isovalerianicum , lactose monohydrate , magnesium stearate ) Placebo ( Lactose monohydrate , magnesium stearate ) 11 . Known Lactose intolerance 12 . Use psychological stressmanagement intervention within last 4 week prior Screening Visit 13 . History substance , drug , include nicotine , alcohol abuse within precede 3 month prior Screening Visit 14 . Alcohol , drug , nicotine intake within last 24 hour day 0 randomization confirm positive screening test 15 . Body Mass Index ( BMI ) &gt; 30 kg/m2 16 . Works regularly night shift 17 . Serious , unstable illness include hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic , immunologic hematologic disease define clinical screening interview 18 . Any somatic disease condition Investigator duly assign representative believe could affect ability individual complete study interpretation study result 19 . Participants medical illness may influence brain morphology and/or physiology ( e.g . uncontrolled hypertension , diabetes ) 20 . Participants history one seizures without clear resolve aetiology 21 . Participants claustrophobia 22 . Participants tinnitus 23 . Clinically significant acute illness within 7 day prior randomization 24 . Presence metallic ( ferromagnetic ) implant ( heart pacemaker , aneurysm clip ) , tattoos piercings 25 . Have receive experimental drug use experimental medical device ( participation clinical trial ) within last 30 day study inclusion 26 . Participants whose ability speak lack doubt</criteria>
	<gender>Male</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>